We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+37.22%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$29.1M
(-9%)
Cap. Flow
-$68.9M
Cap. Flow
% of AUM
-23.29%
Top 10 Holdings %
Top 10 Hldgs %
37.63%
Holding
99
New
29
Increased
28
Reduced
20
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
+$7.19M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$6.21M |
| 3 |
VRAY
ViewRay, Inc.
VRAY
|
+$5.34M |
| 4 |
Pliant Therapeutics
PLRX
|
+$4.01M |
| 5 |
Nkarta
NKTX
|
+$3.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$9.29M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$5.87M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$4.91M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$4.34M |
| 5 |
Biogen
BIIB
|
+$4.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
BioAtla
BCAB
$5.61M
| $1.54M | 0.52% |
+4,008
| New | +$1.31M |
|
52
Celldex Therapeutics
CLDX
$3.02B
| $1.5M | 0.51% |
53,275
+16,953
| +47% | +$520K |
|
|
SGEN
53
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.45M | 0.49% |
10,627
-30,160
| -74% | -$4.91M |
|
|
ETNB
54
DELISTED
89bio
ETNB
| $1.45M | 0.49% |
+250,000
| New | +$1.1M |
|
55
Trevi Therapeutics
TRVI
$2.61B
| $1.45M | 0.49% |
+939,265
| New | +$3.08M |
|
|
AMYT
56
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $1.3M | 0.44% |
188,300
+11,991
| +7% | +$89.5K |
|
|
CLYM
57
Climb Bio
CLYM
$692M
| $1.3M | 0.44% |
402,088
-310,921
| -44% | -$992K |
|
58
Altimmune
ALT
$580M
| $1.28M | 0.43% |
+100,469
| New | +$1.48M |
|
|
NGM
59
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $1.24M | 0.42% |
94,517
+6,214
| +7% | +$94.1K |
|
60
CALL
Anavex Life Sciences
AVXL
$250M
| $1.03M | 0.35% |
+100,000
| New | +$1.06M |
|
61
Codexis
CDXS
$159M
| $881K | 0.3% |
145,437
+7,477
| +5% | +$60.1K |
|
62
EyePoint Inc
EYPT
$1.08B
| $857K | 0.29% |
108,285
-89,355
| -45% | -$830K |
|
|
NUVL
63
DELISTED
Nuvalent
NUVL
| $806K | 0.27% |
+41,439
| New | +$694K |
|
|
MRTX
64
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $714K | 0.24% |
10,220
-26,183
| -72% | -$1.94M |
|
|
HZNP
65
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $627K | 0.21% |
10,131
-62,056
| -86% | -$4.34M |
|
66
Stereotaxis
STXS
$133M
| $623K | 0.21% |
346,231
-22,417
| -6% | -$48K |
|
67
Compass Therapeutics
CMPX
$349M
| $598K | 0.2% |
+262,090
| New | +$726K |
|
68
Ascendis Pharma A/S
ASND
$16.5B
| $516K | 0.17% |
+5,000
| New | +$474K |
|
69
MeiraGTx Holdings
MGTX
$1.11B
| $465K | 0.16% |
55,342
+3,276
| +6% | +$28.9K |
|
70
MacroGenics
MGNX
$240M
| $346K | 0.12% |
+100,000
| New | +$383K |
|
71
PUT
Prothena Corp
PRTA
$440M
| $303K | 0.1% |
+5,000
| New | +$158K |
|
|
NCNA
72
NuCana
NCNA
$5.24M
| $282K | 0.1% |
+54
| New | +$389K |
|
73
Praxis Precision Medicines
PRAX
$8.58B
| $227K | 0.08% |
+6,667
| New | +$332K |
|
|
ELOX
74
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $187K | 0.06% |
27,462
+1,425
| +5% | +$17.1K |
|
75
Evogene
EVGN
$5.92M
| $139K | 0.05% |
16,751
-3,481
| -17% | -$33.6K |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Silverarc Capital Management held 99 positions worth $296M, down 9% from $325M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Silverarc Capital Management withdrew a net $68.9M in Q3 2022, closing 20 positions and reducing 20 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $5.87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier.
Against the trend, Silverarc Capital Management opened a new position in Alnylam Pharmaceuticals worth $6.51M.
- Silverarc Capital Management's largest Q3 2022 buy was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M.
- Silverarc Capital Management added most to Poseida Therapeutics, Inc. Common Stock in Q3 2022, an estimated $7.19M increase.
- Silverarc Capital Management's biggest Q3 2022 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.29M.
- Silverarc Capital Management fully exited Apellis Pharmaceuticals in Q3 2022, selling an estimated $5.87M.
- Silverarc Capital Management's ten largest holdings make up 38% of its $296M portfolio in Q3 2022.
- Silverarc Capital Management opened 29 new positions and closed 20 in Q3 2022.
- Silverarc Capital Management's portfolio value fell 9% quarter-over-quarter to $296M.
Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.